Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood eczema and respiratory infections via gut microbiome and immune modulation.

  • 2026-05-28
  • Frontiers in nutrition 13
    • Ke Chen
    • Shanshan Jin
    • Yang Nie
    • Nianyang He
    • Haixia Chen
    • Jie Yuan
    • Xiaohui Li
    • Min-Tze Liong

Study Design

Type
Clinical Trial
Population
360 formula-fed infants and children aged below 3 years old with elevated allergy risk
Methods
randomized, double-blind, placebo-controlled trial, daily B. lactis BLa80 (5 × 10^9 CFU) or placebo for 180 days
Blinding
Double-blind
Duration
180 days
Funding
Unclear

Background

Early childhood is a critical period for immune development, with eczema and respiratory infections representing common health challenges. This study investigated the efficacy of Bifidobacterium animalis subsp. lactis BLa80 in reducing these conditions potentially through gut microbiome modulation.

Methods

In a randomized, double-blind, placebo-controlled trial, 360 formula-fed infants and children aged below 3 years old with elevated allergy risk received daily B. lactis BLa80 (5 × 109 CFU) or placebo for 180 days. Primary outcomes included eczema incidence and symptom burden, with secondary outcomes assessing respiratory infections, gastrointestinal symptoms, gut microbiota composition (16S rRNA sequencing), functional pathways (KEGG analysis), and fecal immune markers (ELISA).

Results

The probiotic group demonstrated significantly reduced eczema incidence (27.6% vs. 69.5%, RR: 0.398, p < 0.001) and upper respiratory tract infections (19.4% vs. 42.5%, RR: 0.457, p < 0.001). Significant reductions were observed in symptom burden, including nasal congestion, vomiting, milk aspiration, and irritability. Microbiota profiling showed enrichment of beneficial taxa (Akkermansia, Fusicatenibacter) with enhanced metabolic pathways including tryptophan metabolism, vitamin biosynthesis, and xenobiotic degradation. Immunological profiling showed maintained human beta-defensin-2 (p = 0.005), increased secretory IgA (p < 0.001), and reduced calprotectin (p < 0.001).

Conclusions

B. lactis BLa80 supplementation effectively reduces eczema and respiratory infections associated with gut microbiome remodeling that may enhance barrier function, immune regulation, and metabolic capacity, supporting its use as a preventive nutritional strategy in early childhood.

Clinical trial registration

ChiCTR2300074956.

Research Insights

Back to top